(Total Views: 115)
Posted On: 08/16/2023 11:32:15 AM
Post# of 25585
$YECO EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic
https://www.accesswire.com/774507/EV-Biologic...herapeutic
TAMPA, FL / ACCESSWIRE / August 16, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product.
Rigorous product analysis has already begun, and the Company has engaged leading independent testing laboratories to perform sophisticated analyses of molecular composition, therapeutic activity, and any potential forms of contamination, to thoroughly validate the product and prepare comprehensive product data specifications that are second to none.
CEO, Daniel Mckinney said: "As stated, creating novel regenerative medicines to promote health and longevity is our top priority - essentially, our goal is to produce the ‘Fountain of Youth'. Most biotech companies only engage in endless rounds of research and development. We now have a product that we intend to start using in clinical trials in Asia, the Middle East and in South America. There is now hope for old age, frailty, and a host of other illnesses with this revolutionary product. "
https://www.accesswire.com/774507/EV-Biologic...herapeutic
TAMPA, FL / ACCESSWIRE / August 16, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product.
Rigorous product analysis has already begun, and the Company has engaged leading independent testing laboratories to perform sophisticated analyses of molecular composition, therapeutic activity, and any potential forms of contamination, to thoroughly validate the product and prepare comprehensive product data specifications that are second to none.
CEO, Daniel Mckinney said: "As stated, creating novel regenerative medicines to promote health and longevity is our top priority - essentially, our goal is to produce the ‘Fountain of Youth'. Most biotech companies only engage in endless rounds of research and development. We now have a product that we intend to start using in clinical trials in Asia, the Middle East and in South America. There is now hope for old age, frailty, and a host of other illnesses with this revolutionary product. "
(0)
(0)
